MAYNF (Mayne Pharma Group) Total Current Assets: $226.7 Mil (As of Dec. 2025)


MAYNF Mayne Pharma Group Ltd MAYNF
43 GF Score
Price $1.65
GF Value $3.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Total Current Assets?

Mayne Pharma Group MAYNF 43 Total Current Assets is $226.7 Mil as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 43/100 and a GF Value™ of $3.41 (Possible Value Trap). The stock has 3 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Mayne Pharma Group's total current assets for the quarter that ended in Dec. 2025 was $226.7 Mil.

Mayne Pharma Group  (OTCPK:MAYNF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Mayne Pharma Group's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=46.316-390.593+0.75 * 127.209+0.5 * 31.559
=-233.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Total Current Assets Related Terms

Mayne Pharma Group Total Current Assets Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Total Current Assets Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 318.45 359.54 371.56 305.84 229.68

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 318.14 305.84 272.01 229.68 226.66
MAYNF
43GF Score
Mayne Pharma Group Ltd MAYNF
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Mayne Pharma Group's Total Current Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=65.367+117.606+32.917+13.792
=229.7

Mayne Pharma Group's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=46.316+127.209+31.559+21.577
=226.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $226.7 Mil mean?
Mayne Pharma Group (MAYNF) has a Total Current Assets of $226.7 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Mayne Pharma Group and its competitors.
Is Mayne Pharma Group's Total Current Assets too high?
Mayne Pharma Group's current Total Current Assets is $226.7 Mil. Overall, Mayne Pharma Group has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Total Current Assets compare to MCK and CAH?
Mayne Pharma Group's Total Current Assets of $226.7 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Distribution company?
A good Total Current Assets depends on the Medical Distribution industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Mayne Pharma Group and its competitors. Mayne Pharma Group's current Total Current Assets is $226.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.41, compared to a current price of $1.65 — trading 51.6% below its estimated fair value. The current Total Current Assets is $226.7 Mil. Mayne Pharma Group's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Total Current Assets is $226.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.65 is trading 51.6% below its estimated GF Value™ of $3.41. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • Total Current Assets: $226.7 Mil
  • GF Value™: $3.41 vs. price of $1.65 (51.6% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
43GF Score

Get the complete analysis for MAYNF

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$3.41
GF Value